Galmed Pharmaceuticals Ltd. GLMD
GLMD
Galmed Pharmaceuticals Ltd. ARTL
Artelo Biosciences, Inc. MLEC
Moolec Science S.A. CERO
CERo Therapeutics Holdings, Inc. XRTX
XORTX Therapeutics Inc. BIVI
BioVie Inc. VRAX
Virax Biolabs Group Limited PTIX
Protagenic Therapeutics, Inc. LIPO
Lipella Pharmaceuticals Inc. LIMN
Liminatus Pharma, Inc. Class A Common Stock
Galmed Pharmaceuticals Ltd. ARTL
Artelo Biosciences, Inc. MLEC
Moolec Science S.A. CERO
CERo Therapeutics Holdings, Inc. XRTX
XORTX Therapeutics Inc. BIVI
BioVie Inc. VRAX
Virax Biolabs Group Limited PTIX
Protagenic Therapeutics, Inc. LIPO
Lipella Pharmaceuticals Inc. LIMN
Liminatus Pharma, Inc. Class A Common Stock
Performance
| Periode | GLMD | ARTL | MLEC | CERO | XRTX | BIVI | VRAX | PTIX | LIPO | LIMN |
|---|---|---|---|---|---|---|---|---|---|---|
| 6M | 5.88 % | -29.90 % | -90.44 % | -79.23 % | 0.31 % | -76.23 % | -40.89 % | -11.60 % | -75.10 % | -74.05 % |
| YTD | -56.63 % | -37.61 % | -91.74 % | -97.97 % | -26.09 % | -91.35 % | -72.45 % | -56.23 % | -81.13 % | -74.05 % |
| 1Y | -60.44 % | -47.29 % | -92.63 % | -98.66 % | -60.15 % | -83.32 % | -62.19 % | -59.36 % | -83.61 % | -74.05 % |
| 3Y | -97.80 % | -79.08 % | -93.28 % | -99.99 % | -89.32 % | -99.31 % | -96.40 % | -90.53 % | -89.57 % | -74.05 % |
| 5Y | -99.75 % | -92.77 % | -93.08 % | -99.99 % | -96.94 % | -99.81 % | -99.67 % | -97.49 % | -89.57 % | -74.05 % |
| 10Y | -99.92 % | -99.03 % | -93.08 % | -99.99 % | -96.94 % | -98.74 % | -99.67 % | -97.49 % | -89.57 % | -74.05 % |
| From the beginning | -99.94 % | -99.03 % | -93.08 % | -99.99 % | -96.94 % | -99.50 % | -99.67 % | -97.49 % | -89.57 % | -74.05 % |